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Background: Cystic  fibrosis   necessitates  long-term  treatment  with multiple   antibiotics 
creating selection pressure for the development  of antibiotic resistance in infecting and/or 
colonizing  organisms,  impacting  on disease  management, morbidity  and   mortality.β- 
lactamase mediated resistance, in particular, was investigated in isolates from cystic fibrosis 
patients  from  the  public  and  private  health  sectors  in   Durban,  South  Africa. Methods: 
Sputum  samples  were  obtained  from  patients attending public and  private cystic fibrosis 
clinics. The patient demographics and clinical data were recorded.  Bacterial isolates were 
subjected  to  minimal  inhibitory  concentration  (MIC)  determinations,  phenotypic screening 
for extended spectrum-beta-lactamases (ESBLs),  AmpC beta-lactamases and metallo-beta- 
lactamases (MBLs), and, PCR and sequencing for blaTEM, blaSHV , blaCTX-M,  blaCMY, blaPER, 
blaVEB,  blaOXA, blaKPC, blaGES,  blaIMP, blaVIM,and blaNDM genes. Results:The most common 
genotype was F508del and the most common pathogen was Pseudomonas aeruginosa with 
susceptibility  to antibiotics ranging from 14-100% with marginal differences between mucoid 
and  non-mucoid  phenotypes.  All  P aeruginosa  isolates were putative ESBL producers and 
75%  were  putative  MBL producers. All  but one isolate carried multiple beta-lactamases from 
2   or  more   different   Ambler classes. Novel TEM-205   (GenBank Accessionno. KC900516) 
was found in a single isolate in combination with NDM-1, reported for the first time in P. 
aeruginosa  in  South  Africa.  TEM-205  showed  5  amino acid changes compared with TEM-
1; viz.,V84I,E104K,R164S,M182T and A184V while novel TEM-213 (GenBank Accession 
no.KC663615),  identified in  three isolates, showed a single amino acid change Y105F. 
Resistance  phenotypes  did  not routinely correlate with genotypes. This is the first report of 
NDM-1 from Burkholderiace pacia complex (Bcc) in South Africa. Conclusion:The co- 
expression  and/or  co-carriage of  Ambler classes A, B and C β-lactamases in various 
permutations in single isolates severely restricts the clinical management of CF not only with 
beta-lactam  antibiotics  but  also   aminoglycosides and  fluoroquinolones, the resistance genes 
of  which  commonly occur on the same genetic determinants of resistance. The presence of  
NDM-1  in  combination  with  the  CMY  AmpC β-lactamases, TEM, SHV and CTX-MESBLs 
is  of  grave  concern  leaving  colistin  as  the  sole  remaining   treatment    option in  this 
pathogen. The incidence,  prevalence  and  susceptibility patterns of different microorganisms in 
the sputa of CF patients should be closely monitored to optimize management and treatment 
options in a disease requiring chronic antibiotic therapy which increases the propensity for the  
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Cystic fibrosis (CF) is the most common and best known genetic disease involving a defect 
intrans-epithelial  chloride (Cl-)  transport  by  mutations  in  the  CF gene on chromosome 7, 
which  codes  for  the cystic fibrosis transmembrane conductance  regulator protein (CFTR). CF 
is  characterized  by  chronic  lung  malfunction, pancreatic insufficiency and high level of 
chloride in sweat [1]. Since the discovery of the CF gene in 1989, more than a thousand 
mutations have been  described. CF is caused  by  the inheritance of  two mutated CF genes, one 
from  each  parent  and  is  inherited in an autosomal recessive manner where each parent of a 
child  with  CF  is  a  carrier of one abnormal CF gene, but is individually healthy [2]. This 
 disease affects persons  without  distinction of  age or sex but  can b a symptomatic in a number 
of cases [1].  In  South  Africa  approximately  in 20  individuals  in the white  population,  1 in 
55  in  the  population  of  mixed  ancestry and up to 1 in 90 black  Africans carry  a CFTR 
mutation according to the South African Cystic Fibrosis Consensus Document 2012. CFTR 
mutations vary considerably between populations and regions of the world with ∆F508 
constituting   approximately  66%  of all CF mutations globall y[3]. The F508DEL mutation 
further accounts for up to  81%  of  all  CF  alleles  in the South African white population[4], 






The  CFTR  protein  is  a cyclica denosine monophosphate (cAMP) mediated chloride channel 
that regulates the ion and water balance across epithelia. Absence of functional CFTR protein 
results  in  an  increased  viscosity  of the exocrine secretions leading to ciliary  dysfunction, 
mucus  impaction  and  chronic  endo-bronchial  infection in   the   lungs. The normal mucus 
clearance  is  mediated  by  a  two-layer liquid system called the  air way surface liquid (ASL). 
The  upper phase is a mucus layer generated by mucins ecretion. The lower phase is a poly- 
anionic  watery  layer  known as a peri-ciliary liquid (PCL). This two layer system permits 
efficient ciliary beating and mucus clearance. The height of the PCL layer is regulated by 
homeostatic  mechanisms which include co-ordinated activities of different ion channels. The 
apical membrane epithelial sodium channel (ENaC) together with the CFTR channel is 
responsible form a intaining the PCL height. In the absence of CFTR function, unrestrained 
sodium ions (Na+) absorption occurs together with failure of active chloride ion (Cl-)  secretion
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which leads to failure of mucus clearance and decrease of airway surface liquid volume if no 





Mutations in CFTR gene are classified into five groups according to their consequences in the 
CFTR protein synthesis and its chloride channel function. The presence of large deletions and 
stop  codon  categorized  under  Class  I result  intruncated and mostly non-functional CFTR. 
Class  II  mutations,  including  the  common F508del, lead to aberrantly folded CFTR protein 
that  is  recognized  by the cell quality control mechanism and subsequently degraded, resulting 
in  the  absence  of  mature  CFTR protein at the apical cell membrane. Class III mutations lead 
to the full-length CFTR protein being incorporated into the cell membrane, but with defective 
regulation  so   that  no  CFTR  function is present. These three classes usually lead to a classic 
CF phenotype  with  pancreatic insufficiency, although the severity of  lung  disease is highly 
variable. CFTR mutations leading to defective  chloride   conductance   are   grouped  Into Class  
IV.  Class V mutations  involve transcription  dys-regulation, resulting  in  a  decreased amount  
of otherwise normal CFTR. The  latter  two  classes are often associated with a milder 





The  primary  cause  of  long  term complication and frequently death among CF patients  is 
chronic bacterial infection of the respiratory tract. The respiratory pathogens most commonly 
associated  with  CF patients are Staphylococcus aureus, Haemophilus influenzae and 
Pseudomonas  aeruginosa.   S. aureus  and  H. I nfluenza  are  isolated early in life of patients 
with  CF  while  nearly  all  CF  patients  become  colonized  with  P.  aeruginosa later in life. 
Other  bacterial  pathogens isolated from CF respiratory tract re generally not persistent 
colonizers.  These   intermitted   species    include   Streptococcus   pneumonia,   Escherichia   
coli, Klebsiella spp., Proteus spp.,Serratia spp., Enterobacter spp.,and Citrobacter spp. Many 
other  opportunistic  bacterial  pathogens  belonging  to  Gram- negative  non-fermenters have 
also  been  isolated  in  the  respiratory  tract  of  CF  patients,  including  other Pseudomonas 
spp., Acinetobacter anitratus, Achromobacter spp., Stenotrophomonas maltophilia and 
Burkholderia  cepacia  complex  (Bcc). Less  often   and  later on in life, CF patients can be 
become infected with organisms like Aspergillus spp., Candida albicans and atypical 
mycobacteria [6]. P. aeruginosa and Bcc are the most problematic bacterial infections and are 
characterized by low responsiveness to antibiotic therapy and significant reduction in
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patient’s  lung  function.  Both  bacteria  pose  the  risk  of epidemic spread within the CF 
 
community,  with the Bcc being distributed among CF patients to much smaller extent (3- 
 





S. aureus  is a Gram-positive coccus that has been describeds a major pathogen in CF and is 
usually the first pathogen to infect and colonize airways of CF patients.  S. aureus is the 
predominant  pathogen in children, reaching a prevalence rate of nearly 50% by the age of 10 
years [8].  Nasal   carriage rates of S. aureus are significantly higher in patients with CF (66%) 
than in   patients   without   CF   (32%)  [9]. Selective media such as mannitol salt agar may be 
used   for   isolation of  S. aureus.  Positive   result of coagulase and deoxyribonuclease tests can 
also   be   used  to distinguish is  organism  from  other Staphylococcus spp[10]. This pathogen 
may  cause  epithelial  damage  which  leads to adherence of  other pathogens. Other studies 
suggest  that S.  aureus is a   co-infective  pathogen  associated  with P. aeruginosa. Both 
pathogens  lead  to  more  intense  inflammatory response. Before the use of  antibiotics in 
treatment   of   S. aureus  infections,   S.  aureus was causative f several deaths in children with 
CF.  Today, this risk is not so serious, but CF patients not given the correct antibiotic therapy 
show  high  prevalence of S. aureus in nasal epithelium. Young patients with mild lung disease 
and colonized with S. aureus or H. influenzae are often treated with oral antibiotics, including 
amoxicillin-clavulanate,t rimethoprim-sulfamethoxazole and cephalexin. If colonized with S. 
aureus  alone,  patients  often  receive   oxacillin,  nafcillin  or  Cephalothin monotherapy [11]. 
Kahl   and   colleagues  (1998)  reported  that  S. aureus sub-population, small colony variant 
(SCV) phenotypes could be recovered from up to 50% of CF patients harboring S. aureus. In 
contrast to S. aureus, SCVs  yield  small,  non-hemolytic,  non-igmented  and  slowly  growing  
colonies  on  enriched  media  such as sheep blood or  chocolate agars, thus making these 





Methicillin-resistant S.aureus (MRSA) has shown a progressive increase in prevalence in CF 
populations. MRSA have been found in both healthcare and community associated S. aureus 
infections.  Hospital-associated  MRSA  (HA-MRSA)  show high prevalence   in older CF 
patients, while community-associatedMRSA(CA-MRSA) strains have been associated with 
younger CF patients[12]. CA-MRSA have the mecA gene on a small mobile staphylococcal 
cassette   chromosome   and   a   unique  virulence factor   in   the   form   of    Panton-Valentine
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leukocidin  (PVL).  PVL   is  a two component   pore-forming  toxin encoded by two co- 
transcribed genes that cause tissue necrosis and leukocyte destruction[9].There are several 
resistance  mechanisms  used  by  S.  aureus  which  include  enzymatic  inactivation  of   the 
antibiotic  (penicillinase   and  aminoglycoside-modification enzymes), alteration of the target 
with  decreased  affinity  for  the  antibiotic, trapping of the antibiotic (for vancomycin and 
possibly  daptomycin)  and  efflux pumps (fluoroquinolones and tetracycline) [13]. Three 
distinctly    different   mechanisms  of  methicillin resistance have been described in S. aureus. 
The best documented and probably most important mechanism is production of a unique, low 
affinity  penicillin-binding  protein,  PBP 2a. Strains possessing PBP 2a  are resistant to 
methicillin, oxacillin, and probably all other currently available beta-lactam antibiotics. The 
second mechanism of reduced susceptibility to methicillin is the hyper-production of 
Staphylococcus penicillinase. Anti-staphylococcal penicillins were  developed to resist the 
hydrolytic  action   of   staphylococcal  penicillinase, but it  appears that some contemporary 
strains  produce  such  large  amounts  of the enzyme that methicillin and oxacillin are slowly 
but appreciably degraded. A third mechanism describes an intermediate level of resistance to 
methicillin  due  to  production  of  modified,  normal  PBPs  with reduced affinity for beta- 
lactams.These strains  produce PBPs1 and  2 of  normal  molecular  size,  but  with  low  affinity 





H.  influenzae is a Gram-negative cocco-bacillus that requires special growth factors, hemin 
(factor   X)  and nicotinamide-adenine-dinucleotide  (NAD   also known  as V factor). H. 
influenzae strains are divided into two groups depending on presence or absence of a 
polysaccharide  capsule  [15]. Non-encapsulated  H.  influenzae is  the one that is mostly 
associated with chronic lung infections and acute exacerbations in CF patients [16].Chocolate 
agar plate with an antimicrobial disk of bacitracin can be used to isolate H. influenzae in 
respiratory  secretion  on   CF patients. H. influenzae can be   differentiated from most other 
species of   Haemophilus  by  its  specific  requirement for both hemin and NAD for growth. H. 
haemolyticus   is   the  other species that also requires both hemin and NAD factors for growth. 
To  differentiate  between  two  species hemolysis must be checked on  blood agar. H. 
haemolyticus    usually  causes  hemolysis  on  these  media, while H.  influenzae  does not; 
although it has  been reported that a  substantial proportion of H. haemolyticus are non- 
hemolytic.. Many non-hemolytic H. haemolyticus  strains  are  mis-identified as H. influenzae.
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Thus, analysis of 16rRNA  or conserved P6 genes or IgA protease genes can be used for 
differentiate these two organisms [15]. 
 
H. influenzae  usually  infects  younger  CF patients. The in ability to detect H.influenzae in 
adult patients  with  CF  could  be  explained  by  this organism being obscured  by mucoid  P. 
aeruginosa [17].  Young patients with mild lung disease and colonized with H. influenzae or 
S.aureus are  often  treated  with  oral  antibiotics   including   amoxicillin-clavulanate, 
trimethoprim-sulfamethoxazole and cephalexin. Patients  colonized   with both H. influenzae 
and S. aureus  may receive combination therapy with  both  a  narrow-spectrum  penicillin  and  
an aminoglycoside such as gentamicin [11].  H. influenzae under goes hyper-mutation which is 
associated   with  resistance  to many antibiotics. The outer membrane f H.influenzae provides 
very little resistance to the penetration of beta-lactams in to the cell compared to 
enterobacteriaceae. This  explains the lower beta-lactam minimum  inhibitory concentration 
(MIC) of both susceptible and resistance strains. Resistance of ampicillin and other β-lactam 
antibiotics is mediated by production of beta-lactamases or alteration of the penicillin binding 
protein  in  strains  lacking  beta-lactamases.Some    strains  possess  both  mechanisms. 
Susceptibility to all beta-lactamsin  H.influenzaeis generally predicted bys usceptibilityt to 




P. aeruginosa is an oxidase-positive Gram-negative motile rod [1].This bacterium is an 
opportunistic  pathogen   which  only  causes diseases in patients with impaired host defenses 
[19].  It   is   more   prevalent  in adult CF patients, as infection has been shown in 20%  CF 
patients  0–2  years  old   while  in   81%  of   adult  groups  (>18 years old) [1]. P. aeruginosa 
isolated from patients with CF can be differentiated in terms of their morphotypes and 
susceptibility profiles. The initial strains that infect CF patients are described as rough or 
planktonic strains. These strains are sensitive to a variety of antibiotics, are motile and 
prototrophic,  and  have  smooth  lipopolysaccharide. The mucoid P. aeruginosa is associated 
with  development  of  chronic   infection  in  CF  patients. These strains are non-motile, have 
rough  lipopolysaccharide  and  are  frequently auxotrophic. An examination of  sputa  from 
patients reveals that mucoid strains are Gram-negative rods in small clusters surrounded by 
amorphous  material   that  stains Gram-negative. This material isapolysaccharide polymer 
referred  to   as   alginate  which   forms   the   biofilm    matrix    and   renders   the    embedded
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Pseudomonas  species  difficult to clear by the immune system. P. aeruginosa cells in biofilms 
are resistant to antibiotics. The mechanisms of resistance in biofilms are unclear  but high 
concentration of  β-lactamases, penetration barriers and slow growth are so me of the factors 
involved in resistance   mechanisms. There  is growing consensus that  lung  pathology  
occurring during the chronic P. aeruginosa  infection   is  due  to  a   large  extent to the immune 
response directed against pseudomonal biofilms [12]. 
 
Isolation of  P. aeruginosa  from respiratory secretions of CF patients is easily accomplished, 
with both rough and mucoid isolates being recovered on agar selective for Gram-negative 
organisms,   such   as    MacConkey   and   eosin    methylene   blue    agar.   Identification   of    
P. aeruginosa  can  be  accomplished  by  positive oxidase test, pigment production and growth 
at 42oC.  Some  strains  lose  their phenotypic appearance as chronic infection progresses. The 
loss   of  these phenotypes is most likely an evolutionary change in which corresponding genes 
are   either   down-regulated  or  los t in a  nutrient-rich environment [12]. The intrinsic and 
acquired antibiotic resistance makes P. aeruginosa one of the most difficult to treat [20]. 
 
 
Several mechanisms are  involved inantibiotic resistance of P.aeruginosa. Efflux pump 
mechanisms  have become broadly recognized  as major components  of resistance to many 
classes  of   antibiotics.  Some  efflux  pumps  selectively  extrude specific antibiotics, while 
others,   referred   to    as  multidrug resistance (MDR) pumps, expel avariety of structurally 
diverse compounds [20]. Efflux systems of the resistance nodulation division (RND) family, 
MexAB-OprM,  MexEF-OprN,   MexCD-OprJ,  and MexXY-OprM  are  well characterized  in 
P. aeruginosa and contribute significantly to antibiotic resistance [21]. 
 
 
Beta-lactam antibiotics are the most common treatment for pseudomonal bacterial infections. 
Production of beta-lactamases is the main mechanism of bacterial resistance to this class of 
antibiotic.  Many   Gram-negative  bacteria  possess  naturally  occurring,  chromosomally 
mediated beta-lactamases [22]. AmpC beta-lactamase is characteristically chromosomally 
encoded  in   P. aeruginosa.  Some a ntibiotics,  such  as the carbapenems, are strong inducers of 
this   beta-lactamase  but are, stable to its hydrolytic effects. Clavulanate can induce expression 
of  the AmpC  beta-lactamase, result in  antagonism  of  the  bactericidal activity of ticarcillin. 
This has led some authors to suggest that ticarcillin-clavulanate be avoided when selecting an 
anti-pseudomonal beta-lactam antibiotic. Stably derepressed mutants that hyper-produce the 
AmpC beta-lactamase  may lead to  resistance   to  ticarcillin,  piperacillin, and  third-generation 
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cephalosporins  [21].  Hyper-production  of  the inducible AmpC beta-lactamase is mostly due 
to the inactivation of the amidase AmpD and two additional AmpD homologues leading to an 
increase of inducer molecules. Hyper-mutationis characterized by an increased spontaneous- 
mutation  rate and seems to  be  an advantage for fast adaptation to a  heterogeneous and 
fluctuating environment,  like  the  lung of a  chronically infected CF patient. Among P. 
aeruginosa  strains  from  CF patients, high proportions are hyper-mutable. Recently, studies 
found  hyper-mutation  to  be the  key factor in development of mutation-mediated multi- 
resistance in patients with chronic P. aeruginosa lung infections [23]. 
 
Some beta-lactamases   are  acquired   such  as  TEM and SHV plasmid  mediated  beta- 
lactamases. Extended-spectrum-beta-lactamases (ESBLs) are beta-lactamases that hydrolyze 
extended  spectrum  cephalosporins  with  an   oxyimino  side  chain. These  cephalosporins 
include cefotaxime, ceftriaxone,  and  ceftazidime,  as  well  as  the  oxyimino-monobactam,  
aztreonam. TEM  and SHV  ESBLs have been  detected in P. aeruginosa and have  minor 
substitutions that greatly extend their hydrolytic spectra with resistance to oxyimino- 
aminothiazolyl-cephalosporins,  monobactams,  and  penicillins  but  not to carbapenems  [24]. 
CTX-M  is  a  recently  described  family  of  the extended-spectrum-beta-lactamases. The name 
CTX reflects the potent hydrolytic activity of these beta-lactamases against cefotaxime [22]. 
CTX-M-1   was   described  for  the  first time in 2006, in a P .aeruginosa strain which was 
isolated  from  the  sputum of a 21-year-old cystic fibrosis patient in Amsterdam [24]. PER-1 
beta-lactamase  efficiently  hydrolyzes  penicillins   and   cephalosporins and  is susceptible to 
clavulanic acid inhibition. The PER-1 beta-lactamase was first detected in strains of  P. 
aeruginosa  isolated  from  Turkey. Later,  it  was  found among the isolates of  Salmonella 
enterica, Proteus mirabilis and  Alcaligenes  faecalis. The OXA-type beta-lactamases  confer 
resistance to ampicillin and cephalothinand are characterized by their high hydrolytic activity 
against oxacillin and cloxacillin and the fact hat they are poorly inhibited by clavulanic acid. 
Amino  acid  substitutions  in OXA enzymes can also give the ESBL phenotype. OXA-type 
ESBLs   have   been   found  mainly in P. aeruginosa. Other uncommon ESBLs such as VEB, 
GES and integron-associated beta-lactamase  (IBC)beta-lactamases are found mainly in P. 
aeruginosa [22]. 
 
Antibiotic-resistant  bacteria linfections are a major public health problem worldwide. Few 
disease  states  have  as  high  a  prevalence  of  antibiotic–resistant infections as does CF. 
Estimates suggest   that   25-45%  of   adult  CF  patients  are  chronically  infected  with  multi-
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resistant bacteria within their airways [25]. Patients with CF are at risk of multi-resistant 
infections because they have endo-bronchial bacterial infections that in most cases cannot be 
eradicated  [26] and frequent   high dose antibiotic   therapy is an essential  part of CF 
management [27]. Patients are exposed to multiple courses of antibiotics both chronically and 
intermittently,  and  this  introduces  selective pressure for the  development of antibiotic 
resistance  in  infecting and/or colonizing organisms impacting on  disease management, 
morbidity  and  mortality [ 26].  Regular  surveillance  of  sputum  cultures  is  thus essential. This 
prospective  study  describes the microbiological profile of cystic fibrosis  in the public  and 
private  health sectors in Durban, South Africa, specifically, the bacterial/fungal  identity of 
isolates from  sputum cultures and the antibiotic susceptibility of bacterial isolates. The 
phenotypic and genotypic antibiotic resistance mechanisms were also delineated. 
 
 






To describe the profile of cystic fibrosis in the public and private health sectors in Durban, in 






1.  To describe the demographic profile of cystic fibrosis patients in the public and private 
healthcare  sectors  of  Durban,  KwaZulu-Natal  in  terms of patient age, date of diagnosis 
and CF mutation from patient clinical records. 
2.  To describe the  microbiological  profile of sputum  obtained  from  CF  patients  in  terms of 
the dentity of the isolates as determined by the Vitek 2 System. 
3. To phenotypically ascertain antibiotic susceptibility profiles against antibiotic panels 
recommended by the CLSI by MIC determinations. 
4.   To phenotypically screen for ESBL production using the double disc synergy test, AmpC 
beta-lactamase production using the cefoxitin disc sensitivity test, inducible AmpC beta- 
lactamase production using the disk antagonism test  and MBL production using the 
imipenem-EDTA combined disk test as appropriate, on the basis of MIC results.
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5.  To delineate the genotypic mechanisms of beta-lactamase-mediated antibiotic resistance  
     by PCR  and  sequencing  of blaTEM, blaSHV blaCTX-M, blaCMY, blaPER, blaVEB, blaOXA,blaKPC, 
blaGES,blaIMP,blaVIM,andblaNDMgenes
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Paper 1 fulfills objectives 1 – 4 while paper 2 further elaborates on these objectives and 



































This prospective, descriptive study describes the demographic and microbiological profiles of 
cystic fibrosis in patients attending the only two dedicated CF clinics in the public and private 
health  sectors in Durban, South Africa. It further presents CF as a microcosm of  selection 
pressure  with a  focus  on beta-lactamase-mediated resistance and reports on two novel TEM 
beta-lactamases, and the appearance of NDM-1 in P. aeruginosa and Bcc from cystic fibrosis 







 The  most  common  genotype  in the study sample which represented 60% of the known 
patient cohort was F508del. 
 The most common pathogen was P. aeruginosa with susceptibility to antibiotics ranging 
from 14-100% with marginal differences between mucoid and non-mucoid phenotypes. 




 All isolates were susceptible to colistin. 
 All but one isolate carried multiple β-lactamases from two or more different Ambler classes. 
 Novel TEM-205 (GenBank Accession no. KC900516) was found in a single isolate in 
combination with NDM-1, reported for the first time in P. aeruginosa in South Africa. 
TEM-205 showed five amino acid changes compared with TEM-1; viz., V84I, E104K, 
R164S, M182T and A184V. 
 Novel TEM-213 (Gen Bank Accession no. KC663615), identified in 3 isolates, showed a 
single amino acid change Y105F. 




The co-expression and /or co-carriage of Ambler classes A, B and C β-lactamases in various 
permutations in single isolates severely restricts the clinical management of CF not only with 





Of  which  commonly  occur  on  the same genetic determinants of resistance. The presence of  
NDM-1 in combination with  the CMY AmpC β-lactamases, TEM,  SHV and CTX-M  ESBLs 
is   of   grave   concern   leaving  colistin  as  the  sole  remaining   treatment   option  in  this  
pathogen. The incidence, prevalence and susceptibility patterns of different microorganisms in 
the sputa of CF patients should be closely monitored to optimize management and treatment 
options in a disease requiring chronic antibiotic therapy which increases the propensity for the 





The  study  sample  was  limited  to  patients that attended the CF clinics during the study 
period. The results cannot be extrapolated to KZN nor South Africa as a whole. 
Patient records, particularly records in the public sector were often incomplete  precluding 
in-depth  correlations  of  pulmonary  function  parameters  (e.g.FEV1) and body nutritional 
status  (BMI) with variables such as CFTR genotype, age at time of CF diagnosis and 





A data base of CF patients needs to be created to obtain an accurate demographic and 
microbiological  profile  that is representative of the CF patient cohort in KwaZulu-Natal 
and South Africa. 
Future   molecular   biology  studies  should   focus on distinct  sub-populations  of  P. 
aeruginosa  isolates  as  there  is evidence of significant variation even within isolates of the 
same colony morphotype  from the same sample and despite  being from single clonal 
lineages [28]. 
Molecular  typing may help to detect the presence of common resistant strains circulating 
among  patients  to  prevent  spread  of   these  strains,  particularly  in   CF patients who 
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